🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Psyence Biomedical Ltd. (PBM)
NASDAQ: PBM · Real-Time Price · USD
2.970
+0.110 (3.85%)
At close: Nov 20, 2026, 4:00 PM EST
3.005
+0.035 (1.19%)
After-hours: Nov 20, 2026, 7:30 PM EST

Company Description

Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines.

Its lead product candidate is NPX-5, a botanical drug candidate that is in Phase IIb clinical study for the treatment of adjustment disorder in patients with cancer in a palliative care setting.

The company is based in Toronto, Canada. Psyence Biomedical Ltd. is a subsidiary of Psyence Group Inc.

Psyence Biomedical Ltd.
Psyence Biomedical logo
CountryCanada
Founded1994
IndustryBiotechnology
SectorHealthcare
Employees12
CEOJody Aufrichtig

Contact Details

Address:
121 Richmond Street West, Penthouse Suite 1300
Toronto, ON M5H 2K1
Canada
Phone416-477-1708
Websitepsyencebiomed.com

Stock Details

Ticker SymbolPBM
ExchangeNASDAQ
Fiscal YearApril - March
Reporting CurrencyUSD
CIK Code1985062
CUSIP Number74449F407
ISIN NumberCA74449F4078
SIC Code2834

Key Executives

NamePosition
Jody AufrichtigCo-Founder, Executive Chairman and Chief Executive Officer
Warwick Ron Corden-LloydChief Financial Officer and Director
Dr. Neil Maresky M.D.Global Head of Clinical Development
Taryn VosGeneral Counsel

Latest SEC Filings

DateTypeTitle
Nov 19, 20266-KReport of foreign issuer
Oct 21, 20266-KReport of foreign issuer
Oct 15, 2026SCHEDULE 13D/AFiling
Oct 5, 2026SCHEDULE 13GFiling
Oct 5, 20266-KReport of foreign issuer
Sep 28, 20266-KReport of foreign issuer
Sep 23, 20266-KReport of foreign issuer
Sep 14, 20266-KReport of foreign issuer
Sep 1, 2026EFFECTNotice of Effectiveness
Aug 26, 2026S-8Securities to be offered to employees in employee benefit plans